We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bioperfectus Obtains CE Mark for SARS-CoV-2 Antigen Rapid Self-Test

By LabMedica International staff writers
Posted on 05 Jan 2022
Print article
Image: Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)
Image: Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) (Photo courtesy of Jiangsu Bioperfectus Technologies Co., Ltd.)

Jiangsu Bioperfectus Technologies Co., Ltd. (Shanghai, China) has obtained CE Mark for its Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test).

The lateral flow test is intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms. It delivers fast results within 15 minutes and is able to detect asymptomatic cases as well as remain effective in the case of variants.

The Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit was previously available as a home test in the German and Austrian markets since May 20th, 2021. With the CE Mark, the test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd. 

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Fixed Speed Tube Rocker
GTR-FS

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more